Clinical trials: Hodgkin´s Lymphoma
Diffuse Large B Cell Lymphoma
A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients
The primary objective of the study is to assess the efficiency of SCT400 plus CHOP versus Rituximab plus CHOP in untreated CD20-positive DLBCL Patients.
- Trial name
- NCT02772822
- Testing
- SCT400 plus CHOP, Rituximab plus CHOP
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Sinocelltech Ltd.
Hematological Diseases, Hematological Malignancies
Exercise During Chemotherapy for Patients With Hematological Malignancies
The trial will evaluate the effects of aerobic exercise in patients undergoing chemotherapy for the treatment of a hematological neoplastic disease.
- Trial name
- NCT00884364
- Testing
- Aerobic exercise, Fatigue counseling
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Charite University, Berlin, Germany
Lymphoma, Mantle-Cell
An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.
This is a pilot study evaluating tumor activity using Positron Emission Tomography, which is also known as a "PET scan". This study will assess the safety of using PD-0332991 in patients with mantle cell lymphoma.
- Trial name
- NCT00420056
- Testing
- PD-0332991
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Pfizer
Lymphoma, Non-Hodgkin Lymphoma
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in…
- Conditions
- Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)
- Trial name
- PRIMAVERA (NCT06137144)
- Testing
- AZD3470, Pembrolizumab
- Where
- 38 sites in United States, Australia and 9 more
- Volunteers
- 161 people
- Sponsor
- AstraZeneca
Follicular Lymphoma, Follicular Non-Hodgkin´s Lymphoma
Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy
Nowadays, therapy with monoclonal antibodies is considered to be a standard treatment that increases the rate of remissions and the overall survival in patients with follicular lymphoma.
- Conditions
- Follicular Lymphoma, Follicular Non-Hodgkin´s Lymphoma, Autologous Effector Lymphocytes
- Trial name
- NCT01329354
- Testing
- Autologous effector lymphocytes expanded ex-vivo
- Where
- Spain
- Volunteers
- 38 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Non-Hodgkin's Lymphoma
Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin's Lymphoma (JCOG9809)
The purpose of this trial is to investigate the clinical benefit of the dose intensified regimen, Bi-CHOP in comparison to standard CHOP for advanced intermediate or high grade non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT00133302
- Testing
- Standard CHOP, Bi-CHOP (dose intensified CHOP)
- Where
- Japan
- Volunteers
- 450 people
- Sponsor
- Japan Clinical Oncology Group
B-cell Acute Lymphoblastic Leukemia (B-ALL)
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).
- Trial name
- ALLight (NCT07109219)
- Testing
- AZD4512 monotherapy
- Where
- 27 sites in United States, Australia and 7 more
- Volunteers
- 83 people
- Sponsor
- AstraZeneca
Hodgkin´s Lymphoma
HD12 for Advanced Stages
This study is designed to test (1) whether the BEACOPP dosage can be reduced to baseline in the last 4 cycles without loss of effectiveness, and (2) whether consolidating irradiation is necessary following effective chemotherapy.
- Trial name
- NCT00265031
- Testing
- Cyclophosphamide, Adriamycin, Etoposide
- Sponsor
- University of Cologne
Ann Arbor Stage I Childhood Hodgkin Lymphoma, Ann Arbor Stage II Childhood Hodgkin Lymphoma
Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma
This laboratory study is collecting and storing samples of tissue and blood from young patients with Hodgkin's lymphoma. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the…
- Conditions
- Ann Arbor Stage I Childhood Hodgkin Lymphoma, Ann Arbor Stage II Childhood Hodgkin Lymphoma, Ann Arbor Stage III Childhood Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Hodgkin Lymphoma
- Trial name
- NCT00900250
- Testing
- Cytology Specimen Collection Procedure
- Where
- 183 sites in United States, Australia and 2 more
- Volunteers
- 1,271 people
- Sponsor
- Children's Oncology Group
Mild and Moderate Atopic Dermatitis Patients, Atopic Dermatitis (AD)
Clinical Trial of an Ointment in Patients With Mild and Moderate Atopic Dermatitis
Atopic dermatitis (AD) is a chronic skin disorder, which negatively impacts up to 20% children and 3% adults in the world. The main AD treatments aim to regress clinical manifestations, improve and restore skin lesions.
- Trial name
- NCT07653386
- Testing
- S.formosum-containing ointment, commercial moisturizer
- Where
- Vietnam
- Volunteers
- 90 people
- Sponsor
- VinUniversity
Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)
Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)
First line therapy for patients with Lymphocyte predominant Hodgkin´s Disease (LPHD) in clinical stage IA using the monoclonal anti-CD20 antibody rituximab
- Trial name
- NCT00346684
- Testing
- Rituximab
- Where
- Germany
- Sponsor
- University of Cologne
Chronic Lymphocytic Leukemia (CLL), Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Background: Bruton s tyrosine kinase inhibitors (BTKi) are used to treat a form of leukemia. But taking BTKi can also increase a person s risk of developing an abnormal heart rhythm. This can cause sudden death.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia, Mantle Cell Lymphoma, Sudden Cardiac Death
- Trial name
- NCT05724121
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Follicular Lymphoma
Evaluation of Patient and Lesion Specific Prognostic Factors for Standard Radioimmunotherapy
MERIT-NHL as an addendum to the International Registry of Radioimmunotherapy (RIT registry) pooling clinical data of patients who suffered from a non-Hodgkin´s lymphoma also includes the documentation of the respective FDG-PET…
- Trial name
- MERIT-NHL (NCT01151358)
- Where
- 4 sites in Germany
- Volunteers
- 150 people
- Sponsor
- University Hospital, Saarland
Non Hodgkin's Lymphoma, Hodgkin Disease
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
The proposed study is based on our observation of paradoxical tumor regression after rejection of the donor graft in conjunction with the results of our murine experiments.
- Conditions
- Non Hodgkin's Lymphoma, Hodgkin Disease, Multiple Myeloma
- Trial name
- RLI (NCT00909948)
- Testing
- Fludarabine and total body irradiation, Total body irradiation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Massachusetts General Hospital
Leukemia, Stem Cell Transplantation
Study of the Trifunctional Antibody FBTA05 and Donor Lymphocyte Infusion in B-cell Lymphoma After Allogeneic Stem Cell Transplantation
This study is an investigator driven, open-label, non-randomized, uncontrolled, dose escalating Phase I/II study evaluating the safety and preliminary efficacy of the trifunctional bispecific antibody FBTA05 in combination with…
- Trial name
- STP-LYM-01 (NCT01138579)
- Testing
- FBTA05
- Where
- Germany
- Sponsor
- Technical University of Munich
Mantle-Cell Lymphoma
Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma
The purpose of this study is to improve the overall survival of Mantle-Cell-Lymphoma (MCL) by a new concept of treatment with primary curative intention consisting of six courses of immunochemotherapy followed by high-dose…
- Trial name
- HD-MCL2003 (NCT00946374)
- Testing
- Immunochemotherapy, High-dose BEAM plus autologous SCT, HLA-identical allogenic SCT
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Heidelberg University
Myeloma, Non Hodgkin's Lymphoma
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)
This study is being conducted to find out how safe and effective different strategies of infection prevention are in comparison to each other, for preventing infection in patients with blood cancers.
- Conditions
- Myeloma, Non Hodgkin's Lymphoma, Leukemia
- Trial name
- NCT07202078
- Testing
- Trimethoprim / Sulfamethoxazole, Immune Globulin Intravenous
- Where
- 3 sites in Australia
- Volunteers
- 900 people
- Sponsor
- Monash University
Lymphoma, Follicular
Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma
The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a treatment for Follicular Lymphoma (FL).
- Trial name
- NCT00092274
- Testing
- HuMax-CD20
- Where
- United States
- Sponsor
- GlaxoSmithKline
Non-hodgkin's Lymphoma
A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
Phase I main objectives: To observe the safety and preliminary efficacy of GNC-035 in patients with relapsed/refractory non-Hodgkin lymphoma and other hematological malignancies, to determine the DLT and MTD, or MAD, and to…
- Trial name
- NCT06066203
- Testing
- GNC-035
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
B-cell Non-Hodgkin's Lymphoma
A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma
This study aims to evaluate the safety, PK and preliminary anti-tumour activity of SHR-A1912 combined with other therapies in patients with B-cell non-Hodgkin 's lymphoma.
- Trial name
- NCT06104553
- Testing
- SHR-A1912; R-Chemo
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.